Filter Results
:
(20)
Show Results For
-
All HBS Web
(115,546)
- Faculty Publications (20)
Show Results For
-
All HBS Web
(115,546)
- Faculty Publications (20)
Page 1 of
20
Results
- October 2023 (Revised October 2023)
- Case
Veeva Systems: The Next Frontier
By: Satish Tadikonda and William Marks
Born out of a desire to bring technological advances in enterprise software into the healthcare vertical, Peter Gassner and Matt Wallach founded Veeva to bring life sciences companies into the digital age for data management in both the commercial and R&D sectors. Over...
View Details
Tadikonda, Satish, and William Marks. "Veeva Systems: The Next Frontier." Harvard Business School Case 824-074, October 2023. (Revised October 2023.)
- October 2023 (Revised October 2023)
- Case
TetraScience: Unlocking the Power of Scientific Data
By: Satish Tadikonda and William Marks
- October 2023 (Revised October 2023)
- Case
Thermo Fisher Scientific: Foray Into Contract Research
By: Satish Tadikonda, William Marks and Kevin Emancipator
- October 2023 (Revised October 2023)
- Case
Alnylam (A): A Loud Silence
By: Satish Tadikonda, William Marks and Shardule Shah
- October 2023
- Case
Catalent: Catalyzing the Next Era of Growth
By: Satish Tadikonda, William Marks and Kevin Emancipator
- October 2023
- Case
Revvity: A Symbol of Change
By: Satish Tadikonda and William Marks
After selling the PerkinElmer name and several ancillary business units, Prahlad Singh (CEO) and his team at the newly christened Revvity faced a challenge on how best to capitalize on the opportunities ahead for the business and emerge as winners within the Life...
View Details
Tadikonda, Satish, and William Marks. "Revvity: A Symbol of Change." Harvard Business School Case 824-071, October 2023.
- September 2023
- Case
THREAD Research: Decentralized Clinical Trials and Beyond
By: Satish Tadikonda, Amanda McEwen and William Marks
- September 2023 (Revised April 2024)
- Case
Atomwise: Strategic Opportunities in AI for Pharma
By: Satish Tadikonda
Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural...
View Details
Tadikonda, Satish. "Atomwise: Strategic Opportunities in AI for Pharma." Harvard Business School Case 824-043, September 2023. (Revised April 2024.)
- August 2023
- Case
Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company
By: Satish Tadikonda and Brad Prosek
- August 2023 (Revised September 2023)
- Case
Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations
By: Satish Tadikonda and Amanda McEwen
- August 2023 (Revised January 2024)
- Case
Jake Becraft and Strand Therapeutics: The Making of an Entrepreneur
By: Satish Tadikonda, William Marks and Ananya Zutshi
- August 2023 (Revised January 2024)
- Case
Three Vignettes of Early Careers in the Life Sciences
By: Satish Tadikonda, Jacqueline Grant and William Marks
- August 2023
- Background Note
A Note on the Differences Between Therapeutics, Medical Devices, and Diagnostics
By: Satish Tadikonda, Ananya Zutshi, Hunter Goble and William Marks
Tadikonda, Satish, Ananya Zutshi, Hunter Goble, and William Marks. "A Note on the Differences Between Therapeutics, Medical Devices, and Diagnostics." Harvard Business School Background Note 824-045, August 2023.
- August 2023 (Revised August 2023)
- Case
Morphic Therapeutic: Making the Initial Pipeline Decisions
By: Satish Tadikonda and Ananya Zutshi
- August 2023
- Case
Sky Therapeutics: Innovating in Digital Therapeutics
By: Satish Tadikonda and Olivia Reszczynski
Shad Faraz and Alex Youssef were intrigued by the opportunities in the relatively new area of Digital Therapeutics. Despite initial successes, early entrants had struggled with reimbursement and revenue-predictability challenges. However, venture investors still...
View Details
Keywords:
Business Startups;
Entrepreneurship;
Mission and Purpose;
Health Industry;
Technology Industry
Tadikonda, Satish, and Olivia Reszczynski. "Sky Therapeutics: Innovating in Digital Therapeutics." Harvard Business School Case 824-023, August 2023.
- July 2023
- Case
HealthVerity: Real World Data and Evidence
By: Satish Tadikonda
Andrew Kress (CEO and founder) and his team had built a promising marketplace business at HealthVerity serving its core market in healthcare, with a focus on pharmaceutical R&D and services. Thus far, HealthVerity’s products had been unique to the pharma and pharma...
View Details
Tadikonda, Satish. "HealthVerity: Real World Data and Evidence." Harvard Business School Case 824-019, July 2023.
- July 2023 (Revised December 2023)
- Case
Miracle Therapeutics (A): Negotiating an IP License
By: Satish Tadikonda, Michael Singer, William Marks and Wendi Yajnik
(General Experience Case) Beth Sharp and Jennifer Brilliant founded Miracle Therapeutics based on intellectual property developed by Brilliant and her post-doctoral student, John Supreme, in Brilliant’s lab at Elite University (EU). Miracle will have to obtain a...
View Details
Tadikonda, Satish, Michael Singer, William Marks, and Wendi Yajnik. "Miracle Therapeutics (A): Negotiating an IP License." Harvard Business School Case 824-020, July 2023. (Revised December 2023.)
- February 2022 (Revised November 2022)
- Case
Nuritas
By: Mitchell Weiss, Satish Tadikonda, Vincent Dessain and Emer Moloney
Nora Khaldi had built a technology “to unlock the power of nature” in the service of extending human lifespan and improving health, and now in April 2020 was debating telling her Board of Directors she wanted to put on ice some of her discoveries. Nuritas, the company...
View Details
Keywords:
Cash Burn;
Cash Flow Analysis;
Pharmaceutical Companies;
Founder;
Artificial Intelligence;
AI;
Entrepreneurship;
Health Testing and Trials;
Health Care and Treatment;
Decision Making;
Market Entry and Exit;
AI and Machine Learning;
Pharmaceutical Industry
Weiss, Mitchell, Satish Tadikonda, Vincent Dessain, and Emer Moloney. "Nuritas." Harvard Business School Case 822-080, February 2022. (Revised November 2022.)